Skip to main

Badi El Osta, MD

Badi El Osta, MD

Background

Badi El Osta, MD is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Board certified in medical oncology and palliative medicine, Dr. El Osta specializes in the prevention and treatment of head and neck, and lung cancers. Since joining the Emory faculty in 2016, he has been actively involved in patient care and clinical research, as well as in the education of Emory University oncology fellows and medical residents at the Atlanta VA Medical Center.

Dr. El Osta serves as the chair of the Cancer Committee for the Atlanta VA Healthcare System. He is a clinical member of the Discovery and Developmental Therapeutics research program at the Winship Cancer Institute of Emory University. He also serves as a member of the Biomedical Committee of the Institutional Review Board at Emory University.

Dr. El Osta holds professional memberships with American Society of Clinical Oncology, Cancer Therapy Evaluation Program, and Eastern Cooperative Oncology Group.

Dr. El Osta received his MD from Saint Joseph's University School of Medicine in Beirut, Lebanon. He completed his residency at Good Samaritan Hospital in Cincinnati, Ohio. Thereafter, he completed three fellowships: Hematology/Oncology at the Medical College of Georgia in Augusta, Georgia; Investigational Cancer Therapeutics (phase 1 clinical trials) and Palliative Care at the University of Texas MD Anderson Cancer Center in Houston, Texas.

Titles & Roles

  • Assistant Professor, Department of Hematology and Medical Oncology
    Emory University School of Medicine

Education & Training

Education

  • Fellowship, Hematology/Oncology, 2016
    Medical College of Georgia
  • Fellowship, , 2013
    MD Anderson Cancer Center
  • Fellowship, , 2007
    MD Anderson Cancer Center
  • Residency, Internal Medicine, 2005
    Good Samaritan Hospital - OH
  • Medical Education, , 1998
    American University of Beirut, Lebanon

Board Certifications

  • Medical Oncology
    American Board of Internal Medicine, 2016
  • Hospice and Palliative Medicine
    American Board of Internal Medicine, 2012

Professional Memberships

  • ASCO
  • ECOG
Title/Journal Authors Publication Date

MET alterations in advanced non-small cell lung cancer.

Current problems in cancer

 GCL Chagas, AR Rangel, B El Osta 01/04/2024

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.

JTO clinical and research reports

 KE Beckermann, CM Bestvina, B El Osta, RE Sanborn, H Borghaei, PE Lammers, G Selvaggi, JG Whisenant, E Heimann-Nichols, L Berry, CY Hsu, Y Shyr, L Horn, H Wakelee 01/02/2024

Is It Prime Time for Perioperative Therapy in Patients With Resectable Non-Small-Cell Lung Cancer?

JCO oncology practice

 B El Osta, O Ababneh 01/09/2023

KRAS G12C mutation: from undruggable target to potentially agnostic biomarker.

Translational lung cancer research

 B El Osta 30/06/2023

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.

Clinical lung cancer

 BE Osta, J Carlisle, C Steuer, S Pakkala, T Leal, M Dhodapkar, Y Liu, Z Chen, T Owonikoko, S Ramalingam 01/11/2022

Novel targeted therapies for advanced non-small lung cancer.

Seminars in oncology

 O Abughanimeh, A Kaur, B El Osta, AK Ganti 01/04/2022

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

 B El Osta, M Behera, S Kim, LD Berry, G Sica, RN Pillai, TK Owonikoko, MG Kris, BE Johnson, DJ Kwiatkowski, LM Sholl, DL Aisner, PA Bunn, FR Khuri, SS Ramalingam 01/05/2019

First Report of Parkinsonism Associated With Indoximod, an Immune-Modulating Agent.

Journal of global oncology

 M Floyd, B El Osta, SC Tang 01/09/2018

Acute blepharitis: an unusual complication of zoledronic acid.

International journal of rheumatic diseases

 LE Osta, BE Osta 01/04/2017

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

Cancer discovery

 DS Hong, VK Morris, B El Osta, AV Sorokin, F Janku, S Fu, MJ Overman, S Piha-Paul, V Subbiah, B Kee, AM Tsimberidou, D Fogelman, J Bellido, I Shureiqi, H Huang, J Atkins, G Tarcic, N Sommer, R Lanman, F Meric-Bernstam, S Kopetz 01/12/2016

Awards

  • ASCO Foundation Pain Merit Award, 2006
  • ASCO Foundation Oncology Merit Award, 2007

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.